Flavonoids and Alzheimer's disease: reviewing the evidence for neuroprotective potential
- PMID: 38568359
- DOI: 10.1007/s11010-023-04922-w
Flavonoids and Alzheimer's disease: reviewing the evidence for neuroprotective potential
Abstract
Neurodegeneration, which manifests as several chronic and incurable diseases, is an age-related condition that affects the central nervous system (CNS) and poses a significant threat to the public's health for the elderly. Recent decades have experienced an alarming increase in the incidence of neurodegenerative disorders (NDDs), a severe public health issue due to the ongoing development of people living in modern civilizations. Alzheimer's disease (AD) is a leading trigger of age-related dementia. Currently, there are no efficient therapeutics to delay, stop, or reverse the disease's course development. Several studies found that dietary bioactive phytochemicals, primarily flavonoids, influence the pathophysiological processes underlying AD. Flavonoids work well as a supplement to manufactured therapies for NDDs. Flavonoids are effective in complementing synthetic approaches to treat NDDs. They are biologically active phytochemicals with promising pharmacological activities, for instance, antiviral, anti-allergic, antiplatelet, anti-inflammatory, antitumor, anti-apoptotic, and antioxidant effects. The production of nitric oxide (NO), tumor necrosis factor (TNF-α), and oxidative stress (OS) are downregulated by flavonoids, which slow the course of AD. Hence, this research turned from preclinical evidence to feasible clinical applications to develop newer therapeutics, focusing on the therapeutic potential of flavonoids against AD.
Keywords: Alzheimer’s disease; Amyloid-beta; Flavonoids; Neurodegeneration; Neurofibrillary tangles; Neuroprotection; Oxidative stress; Reactive oxygen species.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Role of Plant-Derived Flavonoids and Their Mechanism in Attenuation of Alzheimer's and Parkinson's Diseases: An Update of Recent Data.Molecules. 2018 Apr 2;23(4):814. doi: 10.3390/molecules23040814. Molecules. 2018. PMID: 29614843 Free PMC article. Review.
-
Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects.Neurochem Res. 2024 Aug;49(8):1926-1944. doi: 10.1007/s11064-024-04177-x. Epub 2024 Jun 1. Neurochem Res. 2024. PMID: 38822985 Review.
-
The Role of Selected Bioactive Compounds in the Prevention of Alzheimer's Disease.Antioxidants (Basel). 2020 Mar 11;9(3):229. doi: 10.3390/antiox9030229. Antioxidants (Basel). 2020. PMID: 32168776 Free PMC article. Review.
-
Evaluating Cannabis sativa L.'s neuroprotection potential: From bench to bedside.Phytomedicine. 2022 Dec;107:154485. doi: 10.1016/j.phymed.2022.154485. Epub 2022 Sep 29. Phytomedicine. 2022. PMID: 36209703 Review.
-
Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease.J Food Biochem. 2022 Dec;46(12):e14415. doi: 10.1111/jfbc.14415. Epub 2022 Sep 15. J Food Biochem. 2022. PMID: 36106706 Review.
References
-
- Mao Z, Zheng YL, Zhang YQ et al (2007) The anti-apoptosis effects of daidzein in the brain of D-galactose treated mice. Molecules 12:1455–1470. https://doi.org/10.3390/12071455 - DOI - PubMed - PMC
-
- Hussain G, Schmitt F, Henriques A et al (2013) Systemic down-regulation of delta-9 desaturase promotes muscle oxidative metabolism and accelerates muscle function recovery following nerve injury. PLoS One. https://doi.org/10.1371/journal.pone.0064525 - DOI - PubMed - PMC
-
- Zhao M, Su J, Head E, Cotman CW (2003) Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer’s disease. Neurobiol Dis 14:391–403. https://doi.org/10.1016/j.nbd.2003.07.006 - DOI - PubMed
-
- Argüelles S, Guerrero-Castilla A, Cano M et al (2019) Advantages and disadvantages of apoptosis in the aging process. Ann N Y Acad Sci 1443:20–33. https://doi.org/10.1111/nyas.14020 - DOI - PubMed
-
- Eliwa H, Brizard B, Le Guisquet AM et al (2021) Adult neurogenesis augmentation attenuates anhedonia and HPA axis dysregulation in a mouse model of chronic stress and depression. Psychoneuroendocrinology. https://doi.org/10.1016/j.psyneuen.2020.105097 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
